Mosunetuzumab Expands Promise in Mantle Cell and Marginal Zone Lymphoma: Phase II Results
Mosunetuzumab showed early promise for improving outcomes in two key lymphoma subtypes with 88% response rates in MCL.
Marginal Zone Lymphoma
Latest Post
No posts found in this category.
